ASIT – A SOLUTION IN ALLERGY TREATMENT
https://doi.org/10.21518/2079-701X-2017-9-116-119
Abstract
This article discusses the place and role of an allergen-specific immunotherapy in the treatment of allergic diseases. It provides an action mechanism, indications for use, contraindications, and side effects of an allergen-specific immunotherapy. A comparison of different methodologies for an allergen-specific immunotherapy was made. The advantages of sublingual allergen-specific
immunotherapy in paediatric practice were demonstrated. Provides data on the efficiency and safety of pollinosis sublingual immunotherapy with sensitization to grass
About the Author
S. V. TSAREV
Institute of Immunology of the Federal Medical and Biological Agency of Russia
Russian Federation
MD
Russian Federation
MD
References
1. Marogna M, Bruno M, Massolo A, Falagiani P. Long-lasting effects of sublingual immunotherapy for house dust mites in allergic rhinitis with bronchial hyperreactivity: a long-term(13-year) retrospective study in real life. Int Arch Allergy Immunol, 2007, 142: 70-78.
2. Jacobsen L, Wahn U, Bilo M. B. Allergen-specific immunotherapy provides immediate, long-term and preventive clinical effects in children and adults: the effects of immunotherapy can be categorised by level of benefit -the centenary of allergen specific subcutaneous immunotherapy. Clinical and Translational Allergy, 2012, 2: 8-10.
3. Calderon MA, Cox L, Casale TB, Moingeon P, Demoly P. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence. J Allergy Clin Immunol, 2012, 129: 929-34.
4. Pitsios C, Demoly P, Bilò MB, Gerth van Wijk R, Pfaar O, Sturm GJ, et al. Clinical contraindications to allergen immunotherapy: an EAACI position paper. Allergy, 2015, 70(8): 897-909.
5. WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy, 1998, 53(44): 1-42.
6. Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling H-J, Valovirta E. Standards for practical allergen-specific immunotherapy. Allergy, 2006, 61(82): 1-20.
7. Devillier Ph, Dreyfus J-F, Demoly P, Calderón MA. A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis. BMC Medicine, 2014, 1, 12: 71-74.
8. Wahn V, Tabar A, Kuna P. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunolog, 2009, 123: 160-166.
9. Didier A, Worm M, Horak F. Sustained 3-yearefficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunology, 2011, 128: 559-566.
10. Didier A, Malling H-J, Worm M, Horak F, Sussman GL. Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score. Clinical and Translational Allergy, 2015, 5: 12.
11. Jutel M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W, et al. International consensus on allergy immunotherapy. Allergy Clin. Immunol, 2015, 136(3): 556-68.
Review
For citations:
TSAREV SV. ASIT – A SOLUTION IN ALLERGY TREATMENT. Meditsinskiy sovet = Medical Council. 2017;(9):116-119. (In Russ.) https://doi.org/10.21518/2079-701X-2017-9-116-119
Views:
735
Email this article 